Your browser doesn't support javascript.
loading
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
Nelson, Adam J; Pagidipati, Neha J; Aroda, Vanita R; Cavender, Matthew A; Green, Jennifer B; Lopes, Renato D; Al-Khalidi, Hussein; Gaynor, Tanya; Kaltenbach, Lisa A; Kirk, Julienne K; Lingvay, Ildiko; Magwire, Melissa L; O'Brien, Emily C; Pak, Jonathan; Pop-Busui, Rodica; Richardson, Caroline R; Reed, Monica; Senyucel, Cagri; Webb, Laura; McGuire, Darren K; Granger, Christopher B.
Afiliação
  • Nelson AJ; Duke Clinical Research Institute, Durham, NC (A.J.N., N.J.P., J.B.G., R.D.L., H.A., L.A.K., E.C.O., M.R., L.W., C.B.G.).
  • Pagidipati NJ; Duke Clinical Research Institute, Durham, NC (A.J.N., N.J.P., J.B.G., R.D.L., H.A., L.A.K., E.C.O., M.R., L.W., C.B.G.).
  • Aroda VR; Brigham and Women's Hospital, Boston, MA (V.R.A.).
  • Cavender MA; University of North Carolina, Chapel Hill (M.A.C.).
  • Green JB; Duke Clinical Research Institute, Durham, NC (A.J.N., N.J.P., J.B.G., R.D.L., H.A., L.A.K., E.C.O., M.R., L.W., C.B.G.).
  • Lopes RD; Duke Clinical Research Institute, Durham, NC (A.J.N., N.J.P., J.B.G., R.D.L., H.A., L.A.K., E.C.O., M.R., L.W., C.B.G.).
  • Al-Khalidi H; Duke Clinical Research Institute, Durham, NC (A.J.N., N.J.P., J.B.G., R.D.L., H.A., L.A.K., E.C.O., M.R., L.W., C.B.G.).
  • Gaynor T; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT (T.G., J.P.).
  • Kaltenbach LA; Duke Clinical Research Institute, Durham, NC (A.J.N., N.J.P., J.B.G., R.D.L., H.A., L.A.K., E.C.O., M.R., L.W., C.B.G.).
  • Kirk JK; Wake Forest School of Medicine, Winston-Salem, NC (J.K.K.).
  • Lingvay I; University of Texas Southwestern Medical Center, Dallas (I.L., D.K.).
  • Magwire ML; St Luke's Health System, Kansas City, MO (M.L.M.).
  • O'Brien EC; Duke Clinical Research Institute, Durham, NC (A.J.N., N.J.P., J.B.G., R.D.L., H.A., L.A.K., E.C.O., M.R., L.W., C.B.G.).
  • Pak J; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT (T.G., J.P.).
  • Pop-Busui R; University of Michigan, Ann Arbor (R.P.-B.).
  • Richardson CR; University of Michigan Medical School, Ann Arbor (C.R.R.).
  • Reed M; Duke Clinical Research Institute, Durham, NC (A.J.N., N.J.P., J.B.G., R.D.L., H.A., L.A.K., E.C.O., M.R., L.W., C.B.G.).
  • Senyucel C; Eli Lilly and Company, Indianapolis, IN (C.S.).
  • Webb L; Duke Clinical Research Institute, Durham, NC (A.J.N., N.J.P., J.B.G., R.D.L., H.A., L.A.K., E.C.O., M.R., L.W., C.B.G.).
  • McGuire DK; Parkland Health and Hospital System, Dallas, TX (D.K.M.).
  • Granger CB; Duke Clinical Research Institute, Durham, NC (A.J.N., N.J.P., J.B.G., R.D.L., H.A., L.A.K., E.C.O., M.R., L.W., C.B.G.).
Circulation ; 144(1): 74-84, 2021 07 06.
Article em En | MEDLINE | ID: mdl-34228476
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cardiologia / Doenças Cardiovasculares / Comportamento de Redução do Risco / Receptor do Peptídeo Semelhante ao Glucagon 1 / Inibidores do Transportador 2 de Sódio-Glicose / Nefropatias Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Circulation Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cardiologia / Doenças Cardiovasculares / Comportamento de Redução do Risco / Receptor do Peptídeo Semelhante ao Glucagon 1 / Inibidores do Transportador 2 de Sódio-Glicose / Nefropatias Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Circulation Ano de publicação: 2021 Tipo de documento: Article